Skip to main content

Table 2 Haematological adverse events during observation period (n = 64)

From: Bone marrow impairment during early [177Lu]PSMA-617 radioligand therapy: Haematotoxicity or tumour progression?

 

CTCAE equivalent grading of HP at baseline

CTCAE during 2 cycles of PSMA-RLT

Grade 1

Grade 2

Grade 3

Grade 4

Grade 1

Grade 2

Grade 3

Grade 4

Anaemia

43 (67)

9 (14)

2 (3)

0

7 (11)

8 (13)

5 (8)

0

Thrombopenia

8 (13)

1 (2)

0

0

9 (14)

1 (2)

2 (3)

0

Leukopenia

9 (14)

2 (3)

0

0

6 (9)

5 (8)

1 (2)

0

  1. Data are presented as number of patients with percentage of patients in parentheses; CTCAE = Common Toxicity Criteria for Adverse Events version 5.0 [10]